Carl Zeiss Meditec (CZM) released a mixed set of Q1 17/18 results, in which sales came in above our estimates but profitability was a tad below expectations. Revenue at CER increased by 9.5% driven by strong growth momentum in the Microsurgery segment (+13.4%; accounts for c.27% of sales). Robust demand for recently-launched products bolstered growth during the quarter (neurosurgery platform KINEVO 900 and dental microscope EXTARO 300). The Ophthalmic Devices segment also performed well (+8.2
15 Feb 2018
Growth driven by new product launches; cataract laser project shelved
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth driven by new product launches; cataract laser project shelved
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
15 Feb 2018 -
Author:
Sumit Sayal -
Pages:
3
Carl Zeiss Meditec (CZM) released a mixed set of Q1 17/18 results, in which sales came in above our estimates but profitability was a tad below expectations. Revenue at CER increased by 9.5% driven by strong growth momentum in the Microsurgery segment (+13.4%; accounts for c.27% of sales). Robust demand for recently-launched products bolstered growth during the quarter (neurosurgery platform KINEVO 900 and dental microscope EXTARO 300). The Ophthalmic Devices segment also performed well (+8.2